panitumumabum - Резултати претраге

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

lonsurf 15mg6.14mg tablets

servier laboratories ltd - trifluridine; tipiracil hydrochloride - tablet - 15mg ; 6.14mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

lonsurf 20mg8.19mg tablets

servier laboratories ltd - tipiracil hydrochloride; trifluridine - tablet - 8.19mg ; 20mg

Канада - Енглески - Health Canada

lonsurf tablet

taiho pharma canada, inc. - trifluridine; tipiracil (tipiracil hydrochloride) - tablet - 15mg; 6.14mg - trifluridine 15mg; tipiracil (tipiracil hydrochloride) 6.14mg - antineoplastic agents

Канада - Енглески - Health Canada

lonsurf tablet

taiho pharma canada, inc. - trifluridine; tipiracil (tipiracil hydrochloride) - tablet - 20mg; 8.19mg - trifluridine 20mg; tipiracil (tipiracil hydrochloride) 8.19mg - antineoplastic agents

Европска Унија - Енглески - EMA (European Medicines Agency)

zirabev

pfizer europe ma eeig - bevacizumab - colorectal neoplasms; breast neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastic agents - zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status.zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.zirabev, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.